Affiliation:
1. The University of Texas Southwestern Medical Center
2. Mayo Clinic
3. Vanderbilt University Medical Center
4. University of California, San Diego
Abstract
Hematopoietic stem cell transplantation (HSCT) is a cornerstone of modern medical practice, and can only be performed safely and effectively with appropriate transfusion medicine support. Patients undergoing HSCT often develop therapy-related cytopenia, necessitating differing blood product requirements in the pre-, peri-, and post-transplant periods. Moreover, ensuring optimal management for patients alloimmunized to human leukocyte antigens (HLA) and/or red blood cell (RBC) antigens, as well as for patients receiving ABO-incompatible transplants, requires close collaboration with transfusion medicine and blood bank professionals. Finally, as updated transfusion guidelines and novel blood product modifications emerge, the options available to the transplant practitioner continue to expand. Herein, we detail contemporary blood transfusion and transfusion medicine practices for patients undergoing HSCT.
Reference86 articles.
1. Pre-transplant thrombocytopenia predicts engraftment time and blood products requirement in allogeneic hematopoietic stem cell transplantation patients;Elham Roshandel;Transfusion and Apheresis Science,2020
2. 11. HEMATOPOIETIC CELLULAR THERAPY Accreditation Manual. 8.2 ed. 2021: FOUNDATION FOR THE ACCREDITATION OF CELLULAR THERAPY & JOINT ACCREDITATION COMMITTEE
3. Molecular matching for Rh and K reduces red blood cell alloimmunisation in patients with myelodysplastic syndrome;G.A., et al. Guelsin;Blood Transfus,2015
4. Adverse transfusion reactions in patients with aplastic anaemia or myelodysplastic syndromes;Pierre Moncharmont;Vox Sanguinis,2019
5. Red cell transfusion in alloimmunised allogeneic stem cell transplant patients;Jacinta Perram;Pathology,2022
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献